Research Progress on the Role of Epigenetic Methylation Modification in Hepatocellular Carcinoma

References

• Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–263. doi:10.3322/caac.21834
   PubMed Web of Science ®Google Scholar
• Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global burden of liver disease: 2023 update. J Hepatol. 2023;79(2):516–537. doi:10.1016/j.jhep.2023.03.017
   PubMed Web of Science ®Google Scholar
• Cho Y, Kim BH, Park JW. Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: an Asian perspective comparison. Clin Mol Hepatol. 2023;29(2):252–262. doi:10.3350/cmh.2023.0099
   PubMed Web of Science ®Google Scholar
• Wen N, Cai Y, Li F, et al. The clinical management of hepatocellular carcinoma worldwide: a concise review and comparison of current guidelines: 2022 update. Biosci Trends. 2022;16(1):20–30. doi:10.5582/bst.2022.01061
   PubMed Web of Science ®Google Scholar
• Xie D, Shi J, Zhou J, Fan J, Gao Q. Clinical practice guidelines and real-life practice in hepatocellular carcinoma: a Chinese perspective. Clin Mol Hepatol. 2023;29(2):206–216. doi:10.3350/cmh.2022.0402
   PubMed Web of Science ®Google Scholar
• Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128(4):683–692. doi:10.1016/j.cell.2007.01.029
   PubMed Web of Science ®Google Scholar
• Hlady RA, Robertson KD. Epigenetic memory of environmental exposures as a mediator of liver disease. Hepatology. 2023. doi:10.1097/HEP.0000000000000414
   PubMedGoogle Scholar
• Nepal C, Andersen JB. Alternative promoters in CpG depleted regions are prevalently associated with epigenetic misregulation of liver cancer transcriptomes. Nat Commun. 2023;14(1):2712. doi:10.1038/s41467-023-38272-4
   PubMed Web of Science ®Google Scholar
• Gou D, Liu R, Shan X, et al. Gluconeogenic enzyme PCK1 supports S-adenosylmethionine biosynthesis and promotes H3K9me3 modification to suppress hepatocellular carcinoma progression. J Clin Invest. 2023;133(13). doi:10.1172/JCI161713
   Web of Science ®Google Scholar
• Madkour MM, Ramadan WS, Saleh E, El-Awady R. Epigenetic modulations in cancer: predictive biomarkers and potential targets for overcoming the resistance to topoisomerase I inhibitors. Ann Med. 2023;55(1):2203946. doi:10.1080/07853890.2023.2203946
   PubMed Web of Science ®Google Scholar
• Kim SC, Kim DW, Cho EJ, et al. A circulating cell-free DNA methylation signature for the detection of hepatocellular carcinoma. Mol Cancer. 2023;22(1):164. doi:10.1186/s12943-023-01872-1
   PubMed Web of Science ®Google Scholar
• Pan J, Li D, Fan X, et al. Aberrant DNA Methylation Patterns of Deleted in Liver Cancer 1 Isoforms in Hepatocellular Carcinoma. DNA Cell Biol. 2023;42(3):140–150. doi:10.1089/dna.2022.0384
   PubMed Web of Science ®Google Scholar
• Sun L, Lu J, Li K, et al. Diagnostic and prognostic value of STAP1 and AHNAK methylation in peripheral blood immune cells for HBV-related hepatopathy. Front Immunol. 2022;13:1091103. doi:10.3389/fimmu.2022.1091103
   PubMed Web of Science ®Google Scholar
• Costa P, Sales SLA, Pinheiro DP, et al. Epigenetic reprogramming in cancer: from diagnosis to treatment. Front Cell Dev Biol. 2023;11:1116805. doi:10.3389/fcell.2023.1116805
   PubMed Web of Science ®Google Scholar
• Zhi R, Hao P, Li W, Zhao H. Expression of CKS2 in Hepatocellular Carcinoma: correlation with Survival Outcomes and Immune Microenvironment. J Hepatocell Carcinoma. 2023;10:1767–1784. doi:10.2147/JHC.S427624
   PubMed Web of Science ®Google Scholar
• Zhen J, Pan J, Zhou X, et al. FARSB serves as a novel hypomethylated and immune cell infiltration related prognostic biomarker in hepatocellular carcinoma. Aging. 2023;15(8):2937–2969. doi:10.18632/aging.204619
   PubMedGoogle Scholar
• Guo P, Zheng H, Li Y, et al. Hepatocellular carcinoma detection via targeted enzymatic methyl sequencing of plasma cell-free DNA. Clin Clin Epigenet. 2023;15(1):2. doi:10.1186/s13148-022-01420-6
   PubMed Web of Science ®Google Scholar
• Gou D, Liu R, Shan X, et al. Gluconeogenic enzyme PCK1 supports S-adenosylmethionine biosynthesis and promotes H3K9me3 modification to suppress hepatocellular carcinoma progression. J Clin Invest. 2023;133(13).
   Web of Science ®Google Scholar
• Wei H, Yang J, Chen X, et al. BAIAP2L2 is a novel prognostic biomarker related to migration and invasion of HCC and associated with cuprotosis. Sci Rep. 2023;13(1):8692. doi:10.1038/s41598-023-35420-0
   PubMed Web of Science ®Google Scholar
• Li C, Jia Y, Li N, Zhou Q, Liu R, Wang Q. DNA methylation-mediated high expression of CCDC50 correlates with poor prognosis and hepatocellular carcinoma progression. Aging. 2023;15(15):7424–7439. doi:10.18632/aging.204899
   PubMedGoogle Scholar
• Saeki I, Suehiro Y, Yamauchi Y, et al. Methylated SEPT9 assay-based liquid biopsy as a biomarker in molecular targeted agent-treated hepatocellular carcinoma. Hepatol Int. 2023;17(5):1289–1299. doi:10.1007/s12072-023-10488-y
   PubMed Web of Science ®Google Scholar
• Yan J, Zhang MY, Lin J, et al. WHSC1 is involved in DNA damage, cellular senescence and immune response in hepatocellular carcinoma progression. J Cell Mol Med. 2023;27(10):1436–1441. doi:10.1111/jcmm.17743
   PubMed Web of Science ®Google Scholar
• Wen H, Ji T, Lin L, Cheng N, Zhu K, Cao L. High Expression of Ten Eleven Translocation 1 Is Associated with Poor Prognosis in Hepatocellular Carcinoma. Mediators Inflamm. 2023;2023:2664370. doi:10.1155/2023/2664370
   PubMed Web of Science ®Google Scholar
• Zhang Q, Wei T, Yan L, et al. Hypoxia-Responsive lncRNA AC115619 Encodes a Micropeptide That Suppresses m6A Modifications and Hepatocellular Carcinoma Progression. Cancer Res. 2023;83(15):2496–2512. doi:10.1158/0008-5472.CAN-23-0337
   PubMedGoogle Scholar
• Kuang Y, Cheng Y, Wang J, Li H, Cao X, Wang Y. KIAA1429 mediates epithelial mesenchymal transition in sorafenib-resistant hepatocellular carcinoma through m6A methylation modification. Cancer Med. 2023;12(6):7222–7233. doi:10.1002/cam4.5432
   PubMed Web of Science ®Google Scholar
• Liu R, Yin G, Tuo H, et al. METTL3-induced lncRNA GBAP1 promotes hepatocellular carcinoma progression by activating BMP/SMAD pathway. Biol Direct. 2023;18(1):53. doi:10.1186/s13062-023-00409-2
   PubMed Web of Science ®Google Scholar
• Pu J, Xu Z, Huang Y, et al. N(6) -methyladenosine-modified FAM111A-DT promotes hepatocellular carcinoma growth via epigenetically activating FAM111A. Cancer Sci. 2023;114(9):3649–3665. doi:10.1111/cas.15886
   PubMed Web of Science ®Google Scholar
• Wei H, Huang L, Lu Q, et al. N(6)-Methyladenosine-Modified LEAWBIH Drives Hepatocellular Carcinoma Progression through Epigenetically Activating Wnt/β-Catenin Signaling. J Hepatocell Carcinoma. 2023;10:1991–2007. doi:10.2147/JHC.S433070
   PubMed Web of Science ®Google Scholar
• Sun Z, Xue S, Zhang M, et al. Aberrant NSUN2-mediated m(5)C modification of H19 lncRNA is associated with poor differentiation of hepatocellular carcinoma. Oncogene. 2020;39(45):6906–6919. doi:10.1038/s41388-020-01475-w
   PubMed Web of Science ®Google Scholar
• Shi Y, Niu Y, Yuan Y, et al. PRMT3-mediated arginine methylation of IGF2BP1 promotes oxaliplatin resistance in liver cancer. Nat Commun. 2023;14(1):1932. doi:10.1038/s41467-023-37542-5
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhou P, Deng Y, et al. ALKBH5-mediated m(6) A demethylation of TIRAP mRNA promotes radiation-induced liver fibrosis and decreases radiosensitivity of hepatocellular carcinoma. Clin Transl Med. 2023;13(2):e1198. doi:10.1002/ctm2.1198
   PubMed Web of Science ®Google Scholar
• Tang Z, Yang Y, Chen W, Li E, Liang T. Demethylation at enhancer upregulates MCM2 and NUP37 expression predicting poor survival in hepatocellular carcinoma patients. J Transl Med. 2022;20(1):49. doi:10.1186/s12967-022-03249-2
   PubMed Web of Science ®Google Scholar
• Liu J, Jiang J, Mo J, et al. Global DNA 5-Hydroxymethylcytosine and 5-Formylcytosine Contents Are Decreased in the Early Stage of Hepatocellular Carcinoma. Hepatology. 2019;69(1):196–208. doi:10.1002/hep.30146
   PubMed Web of Science ®Google Scholar
• Xiao CL, Zhu S, He M, et al. N(6)-Methyladenine DNA Modification in the Human Genome. Mol Cell. 2018;71(2):306–18 e7. doi:10.1016/j.molcel.2018.06.015
   PubMed Web of Science ®Google Scholar
• Cui B, Fan X, Zhou D, et al. CSF1R methylation is a key regulatory mechanism of tumor-associated macrophages in hepatocellular carcinoma. Oncol Lett. 2020;20(2):1835–1845. doi:10.3892/ol.2020.11726
   PubMed Web of Science ®Google Scholar
• Miao LL, Wang JW, Liu HH, Gao S, Fan YC, Wang K. Hypomethylation of glycine dehydrogenase promoter in peripheral blood mononuclear cells is a new diagnostic marker of hepatitis B virus-associated hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2024;23(1):35–42. doi:10.1016/j.hbpd.2023.02.011
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang JW, Su X, et al. F-box protein 43 promoter methylation as a novel biomarker for hepatitis B virus-associated hepatocellular carcinoma. Front Microbiol. 2023;14:1267844. doi:10.3389/fmicb.2023.1267844
   PubMed Web of Science ®Google Scholar
• Nishikawa M, Okada H, Kawaguchi K, et al. Identification of a Transmembrane Protein Involved in Shear Stress Signaling and Hepatocarcinogenesis After a Sustained Virological Response to Hepatitis C Virus. Cell Mol Gastroenterol Hepatol. 2023;16(2):263–286. doi:10.1016/j.jcmgh.2023.04.006
   PubMed Web of Science ®Google Scholar
• Kuramoto J, Arai E, Fujimoto M, et al. Quantification of DNA methylation for carcinogenic risk estimation in patients with non-alcoholic steatohepatitis. Clin Clin Epigenet. 2022;14(1):168. doi:10.1186/s13148-022-01379-4
   PubMed Web of Science ®Google Scholar
• Zhao Y, Zhao L, Jin H, et al. Plasma methylated GNB4 and Riplet as a novel dual-marker panel for the detection of hepatocellular carcinoma. Epigenetics. 2024;19(1):2299044. doi:10.1080/15592294.2023.2299044
   PubMed Web of Science ®Google Scholar
• Cheng T, Zhou C, Bian S, Sobeck K, Liu Y. Coordinated activation of DNMT3a and TET2 in cancer stem cell-like cells initiates and sustains drug resistance in hepatocellular carcinoma. Cancer Cell Int. 2024;24(1):110. doi:10.1186/s12935-024-03288-3
   PubMed Web of Science ®Google Scholar
• Yu MC, Lee CW, Lin CH, et al. Differential hypermethylation of the VTRNA2-1 promoter in hepatocellular carcinoma as a prognostic factor: tumor marker prognostic study. Int J Surg. 2020;79:282–289. doi:10.1016/j.ijsu.2020.05.016
   PubMed Web of Science ®Google Scholar
• Lin XH, Zhang DY, Liu ZY, et al. lncRNA-AC079061.1/VIPR1 axis may suppress the development of hepatocellular carcinoma: a bioinformatics analysis and experimental validation. J Transl Med. 2022;20(1):379. doi:10.1186/s12967-022-03573-7
   PubMed Web of Science ®Google Scholar
• Tang Y, Wang Y, Xu X, Sun H, Tang W. STEAP4 promoter methylation correlates with tumorigenesis of hepatocellular carcinoma. Pathol Res Pract. 2022;233:153870. doi:10.1016/j.prp.2022.153870
   PubMed Web of Science ®Google Scholar
• Chen Y, Huang W, Ouyang J, Wang J, Xie Z. Identification of Anoikis-Related Subgroups and Prognosis Model in Liver Hepatocellular Carcinoma. Int J Mol Sci. 2023;24(3).
   Web of Science ®Google Scholar
• Liu R, Cao X, Liang Y, et al. Downregulation of ST6GAL1 Promotes Liver Inflammation and Predicts Adverse Prognosis in Hepatocellular Carcinoma. J Inflamm Res. 2022;15:5801–5814. doi:10.2147/JIR.S385491
   PubMed Web of Science ®Google Scholar
• Wei B, Chen H, Chen X, Guo D, Hong L, Zheng S. Sox15 Methylation Inhibits Cell Proliferation Through Wnt Signaling in Hepatocellular Carcinoma. Front Oncol. 2022;12:842312. doi:10.3389/fonc.2022.842312
   PubMed Web of Science ®Google Scholar
• Liu J, Zhang N, Zeng J, et al. N(6) -methyladenosine-modified lncRNA ARHGAP5-AS1 stabilises CSDE1 and coordinates oncogenic RNA regulons in hepatocellular carcinoma. Clin Transl Med. 2022;12(11):e1107. doi:10.1002/ctm2.1107
   PubMed Web of Science ®Google Scholar
• Abo El-Khair SM, Elalfy H, Diasty M, Ebrahim EE, Elsamanoudy AZ. Methylation degree of metalloproteinase inhibitor RECK gene: links to RECK protein level and hepatocellular carcinoma in chronic HCV infection patients. J Biochem Mol Toxicol. 2021;35(10):e22886. doi:10.1002/jbt.22886
   PubMed Web of Science ®Google Scholar
• Long M, Zhou Z, Wei X, et al. A novel risk score based on immune-related genes for hepatocellular carcinoma as a reliable prognostic biomarker and correlated with immune infiltration. Front Immunol. 2022;13:1023349. doi:10.3389/fimmu.2022.1023349
   PubMed Web of Science ®Google Scholar
• Huang Y, Yu Z, Zheng M, Yang X, Huang H, Zhao L. Methylation‑associated inactivation of JPH3 and its effect on prognosis and cell biological function in HCC. Mol Med Rep. 2022;25(4). doi:10.3892/mmr.2022.12640
   Web of Science ®Google Scholar
• Ahn HR, Baek GO, Yoon MG, et al. Hypomethylation-mediated upregulation of the WASF2 promoter region correlates with poor clinical outcomes in hepatocellular carcinoma. J Exp Clin Cancer Res. 2022;41(1):158. doi:10.1186/s13046-022-02365-7
   PubMed Web of Science ®Google Scholar
• Wang W, Ding B, Lou W, Lin S. Promoter Hypomethylation and miR-145-5p Downregulation- Mediated HDAC11 Overexpression Promotes Sorafenib Resistance and Metastasis of Hepatocellular Carcinoma Cells. Front Cell Dev Biol. 2020;8:724. doi:10.3389/fcell.2020.00724
   PubMed Web of Science ®Google Scholar
• Chen MM, Zhao RC, Chen KF, et al. Hypomethylation of CTCFL promoters as a noninvasive biomarker in plasma from patients with hepatocellular carcinoma. Neoplasma. 2020;67(4):909–915. doi:10.4149/neo_2020_190819N789
   PubMed Web of Science ®Google Scholar
• Kong R, Zhang H, Jia Y, Man Q, Liu S. Integrated analysis revealing the role of TET3-mediated MUC13 promoter hypomethylation in hepatocellular carcinogenesis. Epigenomics. 2022;14(24):1579–1591. doi:10.2217/epi-2022-0395
   PubMed Web of Science ®Google Scholar
• Lee YR, Kim G, Lee HW, et al. Long interspersed nuclear element-1 hypomethylation is associated with poor outcomes via the activation of ST18 in human hepatocellular carcinoma. Medicine (Baltimore). 2021;100(16):e25552. doi:10.1097/MD.0000000000025552
   PubMed Web of Science ®Google Scholar
• Liu HH, Fang Y, Wang JW, et al. Hypomethylation of the cyclin D1 promoter in hepatitis B virus-associated hepatocellular carcinoma. Medicine (Baltimore). 2020;99(20):e20326. doi:10.1097/MD.0000000000020326
   PubMed Web of Science ®Google Scholar
• Li Z, Li Z, Wang L, Long C, Zheng Z, Zhuang X. ZCCHC13-mediated induction of human liver cancer is associated with the modulation of DNA methylation and the AKT/ERK signaling pathway. J Transl Med. 2019;17(1):108. doi:10.1186/s12967-019-1852-0
   PubMed Web of Science ®Google Scholar
• Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet. 2012;13(7):484–492. doi:10.1038/nrg3230
   PubMed Web of Science ®Google Scholar
• Liu Y, Cheng H, Cheng C, et al. ZNF191 alters DNA methylation and activates the PI3K-AKT pathway in hepatoma cells via transcriptional regulation of DNMT1. Cancer Med. 2022;11(5):1269–1280. doi:10.1002/cam4.4535
   PubMed Web of Science ®Google Scholar
• Lu W, Kang Y. Epithelial-Mesenchymal Plasticity in Cancer Progression and Metastasis. Dev Cell. 2019;49(3):361–374. doi:10.1016/j.devcel.2019.04.010
   PubMed Web of Science ®Google Scholar
• Zhao NH, Qian Y, Wu CS, et al. Diagnostic value of NKG2D promoter methylation in hepatitis B virus-associated hepatocellular carcinoma. Biomarker Med. 2019;13(13):1093–1105. doi:10.2217/bmm-2019-0102
   PubMed Web of Science ®Google Scholar
• Wang N, Zhou X, Tang F, Wang X, Zhu X. Identification of LOXL3-associating immune infiltration landscape and prognostic value in hepatocellular carcinoma. Virchows Arch. 2021;479(6):1153–1165. doi:10.1007/s00428-021-03193-4
   PubMed Web of Science ®Google Scholar
• Song G, Zhu X, Xuan Z, et al. Hypermethylation of GNA14 and its tumor-suppressive role in hepatitis B virus-related hepatocellular carcinoma. Theranostics. 2021;11(5):2318–2333. doi:10.7150/thno.48739
   PubMed Web of Science ®Google Scholar
• Song D, Zhou Z, Wu J, et al. DNA methylation regulators-related molecular patterns and tumor immune landscape in hepatocellular carcinoma. Front Oncol. 2022;12:877817. doi:10.3389/fonc.2022.877817
   PubMed Web of Science ®Google Scholar
• Peng X, Lei C, He A, Luo R, Cai Y, Dong W. Upregulation of phosphatidylinositol glycan anchor biosynthesis class C is associated with unfavorable survival prognosis in patients with hepatocellular carcinoma. Oncol Lett. 2021;21(3):237. doi:10.3892/ol.2021.12498
   PubMed Web of Science ®Google Scholar
• Heidari Z, Asemi-Rad A, Moudi B, Mahmoudzadeh-Sagheb H. mRNA expression and epigenetic-based role of chromodomain helicase DNA-binding 5 in hepatocellular carcinoma. J Int Med Res. 2022;50(7):3000605221105344. doi:10.1177/03000605221105344
   Web of Science ®Google Scholar
• Peng H, Du X, Zhang Y. RAB42 is a Potential Biomarker that Correlates With Immune Infiltration in Hepatocellular Carcinoma. Front Mol Biosci. 2022;9:898567. doi:10.3389/fmolb.2022.898567
   PubMed Web of Science ®Google Scholar
• Hur K, Cejas P, Feliu J, et al. Hypomethylation of long interspersed nuclear element-1 (LINE-1) leads to activation of proto-oncogenes in human colorectal cancer metastasis. Gut. 2014;63(4):635–646. doi:10.1136/gutjnl-2012-304219
   PubMed Web of Science ®Google Scholar
• Lu S, Lu H, Jin R, Mo Z. Promoter methylation and H3K27 deacetylation regulate the transcription of VIPR1 in hepatocellular carcinoma. Biochem Biophys Res Commun. 2019;509(1):301–305. doi:10.1016/j.bbrc.2018.12.129
   PubMed Web of Science ®Google Scholar
• Xiang L, Chen LM, Zhai YJ, et al. Hypermethylation of secreted frizzled related protein 2 gene promoter serves as a noninvasive biomarker for HBV-associated hepatocellular carcinoma. Life Sci. 2021;270:119061. doi:10.1016/j.lfs.2021.119061
   PubMed Web of Science ®Google Scholar
• Zhou Y, Qiu XP, Li ZH, et al. Clinical significance of aberrant cyclin-dependent kinase-like 2 methylation in hepatocellular carcinoma. Gene. 2019;683:35–40. doi:10.1016/j.gene.2018.10.009
   PubMed Web of Science ®Google Scholar
• Yan X, Wu T, Tang M, et al. Methylation of the ataxia telangiectasia mutated gene (ATM) promoter as a radiotherapy outcome biomarker in patients with hepatocellular carcinoma. Medicine (Baltimore). 2020;99(4):e18823. doi:10.1097/MD.0000000000018823
   PubMed Web of Science ®Google Scholar
• Wang J, Yu H, Dong W, et al. N6-Methyladenosine-Mediated Up-Regulation of FZD10 Regulates Liver Cancer Stem Cells’ Properties and Lenvatinib Resistance Through WNT/β-Catenin and Hippo Signaling Pathways. Gastroenterology. 2023;164(6):990–1005. doi:10.1053/j.gastro.2023.01.041
   PubMed Web of Science ®Google Scholar
• Fan H, Zhang M, Liu W. Hypermethylated KCNQ1 acts as a tumor suppressor in hepatocellular carcinoma. Biochem Biophys Res Commun. 2018;503(4):3100–3107. doi:10.1016/j.bbrc.2018.08.099
   PubMed Web of Science ®Google Scholar
• Luo H, Xia X, Huang LB, et al. Pan-cancer single-cell analysis reveals the heterogeneity and plasticity of cancer-associated fibroblasts in the tumor microenvironment. Nat Commun. 2022;13(1):6619. doi:10.1038/s41467-022-34395-2
   PubMed Web of Science ®Google Scholar
• Wu M, Lan H, Ye Z, Wang Y. Hypermethylation of the PZP gene is associated with hepatocellular carcinoma cell proliferation, invasion and migration. FEBS Open Bio. 2021;11(3):826–832. doi:10.1002/2211-5463.13093
   PubMed Web of Science ®Google Scholar
• Yuan XD, Wang JW, Fang Y, et al. Pathol Res Pract.2020;216Methylation status of the T-cadherin gene promotor in peripheral blood mononuclear cells is associated with HBV-related hepatocellular carcinoma progression. Pathology, Research and Practice. 2020;216(5):152914. doi:10.1016/j.prp.2020.152914
   PubMed Web of Science ®Google Scholar
• Shi S, Wang B, Wan J, et al. TMEM106A transcriptionally regulated by promoter methylation is involved in invasion and metastasis of hepatocellular carcinoma. Acta Biochim Biophys Sin (Shanghai). 2022;54(7):1008–1020. doi:10.3724/abbs.2022069
   PubMed Web of Science ®Google Scholar
• Huang F, Yang G, Jiang H, et al. Role of Plasma methylated SEPT9 for Predicting Microvascular Invasion and Tumor Proliferation in Hepatocellular Carcinoma. Technol Cancer Res Treat. 2022;21:15330338221144510. doi:10.1177/15330338221144510
   Web of Science ®Google Scholar
• Li B, Huang H, Huang R, et al. SEPT9 Gene Methylation as a Noninvasive Marker for Hepatocellular Carcinoma. Dis Markers. 2020;2020:6289063. doi:10.1155/2020/6289063
   PubMed Web of Science ®Google Scholar
• Wang X, Chen M, Liang X, et al. RNF135 Promoter Methylation Is Associated With Immune Infiltration and Prognosis in Hepatocellular Carcinoma. Front Oncol. 2021;11:752511. doi:10.3389/fonc.2021.752511
   PubMed Web of Science ®Google Scholar
• Galetzka D, Böck J, Wagner L, et al. Hypermethylation of RAD9A intron 2 in childhood cancer patients, leukemia and tumor cell lines suggest a role for oncogenic transformation. EXCLI J. 2022;21:117–143. doi:10.17179/excli2021-4482
   PubMed Web of Science ®Google Scholar
• Khanal T, Rajan N, Li W, Liyanarachchi S, Ringel MD. The RCAN1.4 Metastasis Suppressor Is Hypermethylated at Intron 1 in Thyroid Cancer. Thyroid. 2023;33(8):965–973. doi:10.1089/thy.2022.0687
   PubMed Web of Science ®Google Scholar
• Cui X, Zhang C, Xu Z, et al. Dual CRISPR interference and activation for targeted reactivation of X-linked endogenous FOXP3 in human breast cancer cells. Mol Cancer. 2022;21(1):38. doi:10.1186/s12943-021-01472-x
   PubMed Web of Science ®Google Scholar
• Yang Y, Yan Y, Yin J, et al. O-GlcNAcylation of YTHDF2 promotes HBV-related hepatocellular carcinoma progression in an N(6)-methyladenosine-dependent manner. Signal Transduct Target Ther. 2023;8(1):63. doi:10.1038/s41392-023-01316-8
   PubMed Web of Science ®Google Scholar
• Maron MI, Casill AD, Gupta V, et al. Type I and II PRMTs inversely regulate post-transcriptional intron detention through Sm and CHTOP methylation. Elife. 2022;11.
   Web of Science ®Google Scholar
• Telonis AG, Yang Q, Huang HT, Figueroa ME. MIR retrotransposons link the epigenome and the transcriptome of coding genes in acute myeloid leukemia. Nat Commun. 2022;13(1):6524. doi:10.1038/s41467-022-34211-x
   PubMed Web of Science ®Google Scholar
• Roundtree IA, Evans ME, Pan T, He C. Dynamic RNA Modifications in Gene Expression Regulation. Cell. 2017;169(7):1187–1200. doi:10.1016/j.cell.2017.05.045
   PubMed Web of Science ®Google Scholar
• Kim SC, Kim J, Kim DW, et al. Methylation-sensitive high-resolution melting analysis of the USP44 promoter can detect early-stage hepatocellular carcinoma in blood samples. BMB Rep. 2022;55(11):553–558. doi:10.5483/BMBRep.2022.55.11.110
   PubMed Web of Science ®Google Scholar
• Sun X, Fu S, Yuan X, et al. RNA N6-methyladenosine (m6A) modification in HNSCC: molecular mechanism and therapeutic potential. Cancer Gene Ther. 2023;30(9):1209–1214. doi:10.1038/s41417-023-00628-9
   PubMed Web of Science ®Google Scholar
• Huang X, Wang H, Xu F, et al. Overexpression of chaperonin containing TCP1 subunit 7 has diagnostic and prognostic value for hepatocellular carcinoma. Aging. 2022;14(2):747–769. doi:10.18632/aging.203809
   PubMedGoogle Scholar
• Wang K, Luo L, Fu S, et al. PHGDH arginine methylation by PRMT1 promotes serine synthesis and represents a therapeutic vulnerability in hepatocellular carcinoma. Nat Commun. 2023;14(1):1011. doi:10.1038/s41467-023-36708-5
   PubMed Web of Science ®Google Scholar
• Li W, Liu J, Ma Z, Zhai X, Cheng B, Zhao H. m(6)A RNA Methylation Regulators Elicit Malignant Progression and Predict Clinical Outcome in Hepatocellular Carcinoma. Dis Markers. 2021;2021:8859590. doi:10.1155/2021/8859590
   PubMed Web of Science ®Google Scholar
• Deng M, Fang L, Li SH, et al. Expression pattern and prognostic value of N6-methyladenosine RNA methylation key regulators in hepatocellular carcinoma. Mutagenesis. 2021;36(5):369–379. doi:10.1093/mutage/geab032
   PubMed Web of Science ®Google Scholar
• Collignon E, Cho B, Furlan G, et al. m(6)A RNA methylation orchestrates transcriptional dormancy during paused pluripotency. Nat Cell Biol. 2023;25(9):1279–1289. doi:10.1038/s41556-023-01212-x
   PubMed Web of Science ®Google Scholar
• Yu Y, Lu X, Yan Y, et al. The lncRNA KIF9-AS1 Accelerates Hepatocellular Carcinoma Growth by Recruiting DNMT1 to Promote RAI2 DNA Methylation. J Oncol. 2022;2022:3888798. doi:10.1155/2022/3888798
   PubMed Web of Science ®Google Scholar
• Hou Y, Chen K, Liao R, Li Y, Yang H, Gong J. LINC01419-mediated epigenetic silencing of ZIC1 promotes metastasis in hepatocellular carcinoma through the PI3K/Akt signaling pathway. Lab Invest. 2021;101(5):570–587. doi:10.1038/s41374-021-00539-z
   PubMed Web of Science ®Google Scholar
• Dong ZR, Ke AW, Li T, et al. CircMEMO1 modulates the promoter methylation and expression of TCF21 to regulate hepatocellular carcinoma progression and sorafenib treatment sensitivity. Mol Cancer. 2021;20(1):75. doi:10.1186/s12943-021-01361-3
   PubMed Web of Science ®Google Scholar
• Lv HC, Lv YY, Wang G, et al. Mechanism of miR-424-5p promoter methylation in promoting epithelial-mesenchymal transition of hepatocellular carcinoma cells. Kaohsiung J Med Sci. 2022;38(4):336–346. doi:10.1002/kjm2.12499
   PubMed Web of Science ®Google Scholar
• Ma S, Chen F, Lin C, et al. MiR-186-5p prevents hepatocellular carcinoma progression by targeting methyltransferase-like 3 that regulates m6A-mediated stabilization of follistatin-like 5. Heliyon. 2024;10(5):e26767. doi:10.1016/j.heliyon.2024.e26767
   PubMed Web of Science ®Google Scholar
• Zhuang Q, Dai Z, Xu X, et al. RNA Methyltransferase FTSJ3 Regulates the Type I Interferon Pathway to Promote Hepatocellular Carcinoma Immune Evasion. Cancer Res. 2024;84(3):405–418. doi:10.1158/0008-5472.CAN-23-2049
   PubMed Web of Science ®Google Scholar
• Zhao K, Wei B, Zhang Y, Shi W, Zhang G, Wang Z. M6A regulator-mediated immune infiltration and methylation modification in hepatocellular carcinoma microenvironment and immunotherapy. Front Pharmacol. 2022;13:1052177. doi:10.3389/fphar.2022.1052177
   PubMed Web of Science ®Google Scholar
• Gebauer F, Schwarzl T, Valcárcel J, Hentze MW. RNA-binding proteins in human genetic disease. Nat Rev Genet. 2021;22(3):185–198. doi:10.1038/s41576-020-00302-y
   PubMed Web of Science ®Google Scholar
• Kim GW, Imam H, Khan M, et al. HBV-Induced Increased N6 Methyladenosine Modification of PTEN RNA Affects Innate Immunity and Contributes to HCC. Hepatology. 2021;73(2):533–547. doi:10.1002/hep.31313
   PubMed Web of Science ®Google Scholar
• Du Y, Ma Y, Zhu Q, et al. An m6A-Related Prognostic Biomarker Associated With the Hepatocellular Carcinoma Immune Microenvironment. Front Pharmacol. 2021;12:707930. doi:10.3389/fphar.2021.707930
   PubMed Web of Science ®Google Scholar
• Dominissini D, Moshitch-Moshkovitz S, Schwartz S, et al. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature. 2012;485(7397):201–206. doi:10.1038/nature11112
   PubMed Web of Science ®Google Scholar
• Slobodin B, Han R, Calderone V, et al. Transcription Impacts the Efficiency of mRNA Translation via Co-transcriptional N6-adenosine Methylation. Cell. 2017;169(2):326–37 e12. doi:10.1016/j.cell.2017.03.031
   PubMed Web of Science ®Google Scholar
• Zhu S, Ye H, Xu X, et al. Involvement of TRPC7-AS1 Expression in Hepatitis B Virus-Related Hepatocellular Carcinoma. J Oncol. 2021;2021:8114327. doi:10.1155/2021/8114327
   PubMed Web of Science ®Google Scholar
• Zhao J, Li L, Guo L, et al. Nano-Gold PCR in Detection of TERT Methylation and Its Correlation with Hepatitis B-Related Hepatocellular Carcinoma. J Biomed Nanotechnol. 2021;17(7):1284–1292. doi:10.1166/jbn.2021.3103
   PubMed Web of Science ®Google Scholar
• Chen MH, Fu LS, Zhang F, Yang Y, Wu XZ. LncAY controls BMI1 expression and activates BMI1/Wnt/β-catenin signaling axis in hepatocellular carcinoma. Life Sci. 2021;280:119748. doi:10.1016/j.lfs.2021.119748
   PubMed Web of Science ®Google Scholar
• Lin YH, Zhang BY, Chen ZS. circRERE regulates the expression of GBX2 through miR-1299 and ZC3H13/N(6)-methyladenosine (m(6)A) to promote growth and invasion of hepatocellular carcinoma cells. J Biosci. 2022;47.
   PubMed Web of Science ®Google Scholar
• Wu A, Hu Y, Xu Y, et al. Methyltransferase-Like 3-Mediated m6A Methylation of Hsa_circ_0058493 Accelerates Hepatocellular Carcinoma Progression by Binding to YTH Domain-Containing Protein 1. Front Cell Dev Biol. 2021;9:762588. doi:10.3389/fcell.2021.762588
   PubMed Web of Science ®Google Scholar
• Chi F, Cao Y, Chen Y. Analysis and Validation of circRNA-miRNA Network in Regulating m(6)A RNA Methylation Modulators Reveals CircMAP2K4/miR-139-5p/YTHDF1 Axis Involving the Proliferation of Hepatocellular Carcinoma. Front Oncol. 2021;11:560506. doi:10.3389/fonc.2021.560506
   PubMed Web of Science ®Google Scholar
• Liu L, Gu M, Ma J, et al. CircGPR137B/miR-4739/FTO feedback loop suppresses tumorigenesis and metastasis of hepatocellular carcinoma. Mol Cancer. 2022;21(1):149. doi:10.1186/s12943-022-01619-4
   PubMed Web of Science ®Google Scholar
• Wang W, Huang Q, Liao Z, et al. ALKBH5 prevents hepatocellular carcinoma progression by post-transcriptional inhibition of PAQR4 in an m6A dependent manner. Exp Hematol Oncol. 2023;12(1):1. doi:10.1186/s40164-022-00370-2
   PubMed Web of Science ®Google Scholar
• Song D, An K, Zhai W, et al. NSUN2-mediated mRNA m(5)C Modification Regulates the Progression of Hepatocellular Carcinoma. Genomics Proteomics Bioinf. 2022;21(4):823–833. doi:10.1016/j.gpb.2022.09.007
   PubMed Web of Science ®Google Scholar
• Zheng Q, Yu X, Zhang Q, He Y, Guo W. Genetic characteristics and prognostic implications of m1A regulators in pancreatic cancer. Biosci Rep. 2021;41(4). doi:10.1042/BSR20210337
   Web of Science ®Google Scholar
• Zhao Y, Zhao Q, Kaboli PJ, et al. m1A Regulated Genes Modulate PI3K/AKT/mTOR and ErbB Pathways in Gastrointestinal Cancer. Transl Oncol. 2019;12(10):1323–1333. doi:10.1016/j.tranon.2019.06.007
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang J, Li X, et al. N(1)-methyladenosine methylation in tRNA drives liver tumourigenesis by regulating cholesterol metabolism. Nat Commun. 2021;12(1):6314. doi:10.1038/s41467-021-26718-6
   PubMed Web of Science ®Google Scholar
• Husmann D, Gozani O. Histone lysine methyltransferases in biology and disease. Nat Struct Mol Biol. 2019;26(10):880–889. doi:10.1038/s41594-019-0298-7
   PubMed Web of Science ®Google Scholar
• Guccione E, Richard S. The regulation, functions and clinical relevance of arginine methylation. Nat Rev Mol Cell Biol. 2019;20(10):642–657. doi:10.1038/s41580-019-0155-x
   PubMed Web of Science ®Google Scholar
• Yu L, Ji T, Liao W, et al. H4-methylation regulators mediated epitranscriptome patterns and tumor microenvironment infiltration characterization in hepatocellular carcinoma. Clin Clin Epigenet. 2023;15(1):43. doi:10.1186/s13148-023-01460-6
   PubMed Web of Science ®Google Scholar
• Qian Y, Li Y, Zheng C, et al. High methylation levels of histone H3 lysine 9 associated with activation of hypoxia-inducible factor 1α (HIF-1α) predict patients’ worse prognosis in human hepatocellular carcinomas. Cancer Genet. 2020;245:17–26. doi:10.1016/j.cancergen.2020.04.077
   PubMed Web of Science ®Google Scholar
• Ghobashi AH, Vuong TT, Kimani JW, Ladaika CA, Hollenhorst PC, O’Hagan HM. Activation of AKT induces EZH2-mediated β-catenin trimethylation in colorectal cancer. iScience. 2023;26(9):107630. doi:10.1016/j.isci.2023.107630
   PubMed Web of Science ®Google Scholar
• Guo S, Chen F, Li L, et al. Intracellular Fusobacterium nucleatum infection increases METTL3-mediated m6A methylation to promote the metastasis of esophageal squamous cell carcinoma. J Adv Res. 2023. doi:10.1016/j.jare.2023.08.014
   Google Scholar
• Chen M, Fang Y, Liang M, et al. The activation of mTOR signalling modulates DNA methylation by enhancing DNMT1 translation in hepatocellular carcinoma. J Transl Med. 2023;21(1):276. doi:10.1186/s12967-023-04103-9
   PubMed Web of Science ®Google Scholar
• Fatemiyan N, Davie JR. Broad histone H4 monomethylation marks expressed genes involved in translation. Genome. 2023;66(8):224–234. doi:10.1139/gen-2023-0011
   PubMed Web of Science ®Google Scholar
• Wong TL, Ng KY, Tan KV, et al. CRAF Methylation by PRMT6 Regulates Aerobic Glycolysis-Driven Hepatocarcinogenesis via ERK-Dependent PKM2 Nuclear Relocalization and Activation. Hepatology. 2020;71(4):1279–1296. doi:10.1002/hep.30923
   PubMed Web of Science ®Google Scholar
• Zhao J, O’Neil M, Schonfeld M, Komatz A, Weinman SA, Tikhanovich I. Hepatocellular Protein Arginine Methyltransferase 1 Suppresses Alcohol-Induced Hepatocellular Carcinoma Formation by Inhibition of Inducible Nitric Oxide Synthase. Hepatol Commun. 2020;4(6):790–808. doi:10.1002/hep4.1488
   PubMed Web of Science ®Google Scholar
• Li Y, Dobrolecki LE, Sallas C, et al. PRMT blockade induces defective DNA replication stress response and synergizes with PARP inhibition. Cell Rep Med. 2023;4(12):101326. doi:10.1016/j.xcrm.2023.101326
   PubMedGoogle Scholar
• Kim SY, Hwang S, Lee BR, Hong JA, Sung YH, Kim I. Inhibition of histone demethylase KDM4 by ML324 induces apoptosis through the unfolded protein response and Bim upregulation in hepatocellular carcinoma cells. Chem Biol Interact. 2022;353:109806. doi:10.1016/j.cbi.2022.109806
   PubMed Web of Science ®Google Scholar
• Lin Q, Wu Z, Yue X, et al. ZHX2 restricts hepatocellular carcinoma by suppressing stem cell-like traits through KDM2A-mediated H3K36 demethylation. EBioMedicine. 2020;53:102676. doi:10.1016/j.ebiom.2020.102676
   PubMed Web of Science ®Google Scholar
• Liu Z, Lin M, Liu C, et al. Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma. J Med Chem. 2024;67(8):6313–6326. doi:10.1021/acs.jmedchem.3c02265
   PubMed Web of Science ®Google Scholar
• Zhang S, Guo L, Zhang Z, et al. Type-I protein arginine methyltransferase inhibition primes anti-programmed cell death protein 1 immunotherapy in triple-negative breast cancer. Cancer. 2024;130(S8):1415–1423. doi:10.1002/cncr.35142
   PubMedGoogle Scholar
• Hao M, Jiang Y, Zhang Y, Yang X, Han J. Ferroptosis regulation by methylation in cancer. Biochim Biophys Acta Rev Cancer. 2023;1878(6):188972. doi:10.1016/j.bbcan.2023.188972
   PubMed Web of Science ®Google Scholar
• Mao X, Xu J, Wang W, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. 2021;20(1):131. doi:10.1186/s12943-021-01428-1
   PubMed Web of Science ®Google Scholar
• Fox-Fisher I, Shemer R, Dor Y. Epigenetic liquid biopsies: a novel putative biomarker in immunology and inflammation. Trends Immunol. 2023;44(5):356–364. doi:10.1016/j.it.2023.03.005
   PubMed Web of Science ®Google Scholar